NCT03514121 2024-11-22FPA150-001Five Prime Therapeutics, Inc.Phase EARLY_PHASE1 Terminated95 enrolled 36 charts
NCT02728830 2024-02-21A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic CancersDuke UniversityPhase EARLY_PHASE1 Completed39 enrolled 16 charts
NCT03694834 2023-11-28Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial CancerUNC Lineberger Comprehensive Cancer CenterPhase EARLY_PHASE1 Terminated3 enrolled